Technology ID
E-178-2014-2

Recombinant HIV-1 Envelope Protein for Vaccine Use

Linked ID
TAB-3338
Inventors
Aliaksandr Druz (NIAID)
Baoshan Zhang (NIAID)
Cheng Cheng (NIAID)
Guillaume Stewart-Jones (NIAID)
Gwo-Yu Chuang (NIAID)
Ivelin Georgiev (NIAID)
Jason Gorman (NIAID)
John Mascola (NIAID)
Marie Pancera (NIAID)
Michael Joyce (NIAID)
Peter Kwong (NIAID)
Priyamvada Acharya (NIAID)
Rebecca Lynch (NIAID)
Rita Chen (NIAID)
Tongqing Zhou (NIAID)
Ulrich Baxa (NIAID)
Yongping Yang (NIAID)
Lead Inventors
Peter Kwong (NIAID)
Co-Inventors
Aliaksandr Druz (NIAID)
Baoshan Zhang (NIAID)
Cheng Cheng (NIAID)
Guillaume Stewart-Jones (NIAID)
Gwo-Yu Chuang (NIAID)
Ivelin Georgiev (NIAID)
Jason Gorman (NIAID)
John Mascola (NIAID)
Marie Pancera (NIAID)
Michael Joyce (NIAID)
Priyamvada Acharya (NIAID)
Rebecca Lynch (NIAID)
Rita Chen (NIAID)
Tongqing Zhou (NIAID)
Ulrich Baxa (NIAID)
Yongping Yang (NIAID)
ICs
NIAID
Commercial Applications
  • Vaccine for prevention of HIV-1 infection.
  • Therapeutic vaccine for treatment of HIV-1 infection.
In pursuit of an effective vaccine to end the global HIV-1/AIDS pandemic, researchers at the Vaccine Research Center (“VRC”) continue to study the structure of HIV-1. Recently, these researchers have determined the three-dimensional structure of the HIV-1 Envelope trimeric ectodomain (“Env”), comprised of three gp120 and three gp41 subunits, in its prefusion, mature, closed conformation.

The researchers hypothesize that immunization with the prefusion, closed HIV-1 Env protein will elicit a neutralizing immune response. The VRC researchers engineered a portion of the HIV-1 Env trimer to stabilize it in this closed conformation for use as an immunogen.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.
Competitive Advantages
  • Currently, no licensed HIV-1 vaccine exists.

Request More Info

Licensing Contact